Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho Kicks Off Research Team to Increase Popularity of Switch OTC Drugs
November 22, 2010
- Meiji Seika: Sales Up 10.4% Driven by Generics
November 22, 2010
- Kyowa Kirin: Pharma Sales Up 0.7%
November 22, 2010
- Teva-Kowa, Taisho Pharm. Ind. Integrate R&D Divisions
November 22, 2010
- Teijin: Pharma Sales Up 2.2%
November 22, 2010
- Astellas Sues Nycomed US to Protect Protopic Patents
November 22, 2010
- Sawai Proposes Business Integration to Kyorin
November 22, 2010
- Otsuka HD to Go Public in December
November 22, 2010
- TMX-67 to Be Launched in Japan after Spring 2011
November 22, 2010
- Takeda Accelerates Investment in Bioventures
November 22, 2010
- Takata to Comarket Ecbarl with Shionogi
November 22, 2010
- Asahi Kasei Pharma: Sales Remain Flat Despite Strong Sales of Recomodulin
November 22, 2010
- Janssen Voluntarily Recalls Anticancer Drug Velcade
November 22, 2010
- MTPC to Launch Nearly 10 New Products by FY2015
November 22, 2010
- JT: Pharma Business Driven by Torii
November 22, 2010
- Sales of Ethical Drugs Up 0.2% in September: Crecon Report
November 22, 2010
- Kaken to Increase Its No. of MRs to 800
November 22, 2010
- Yakult Honsha: Elplat Drives Pharma Business
November 22, 2010
- Eribulin Approved by FDA: Eisai
November 22, 2010
- Combined Sales of 23 Listed JPMA Member Companies Up 1.4%
November 22, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…